Evidence map›Paper›PMID 39565468›Full record

Trial reportClinical and experimental nephrology2025

Prospective randomized trial of antibiotic prophylaxis for percutaneous renal biopsy.

Kensei Yahata, Kenichi Koga, Daisuke Hirai, Koichi Seta, Keita P Mori, Yoshiaki Higashi, Tatsuo Tsukamoto, Akira Ishii, Keiichi Kaneko, Motoko Yanagita and 5 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kensei YahataDepartment of Nephrology, Japanese Red Cross Osaka Hospital, 5-30 Fudegasaki-Cho, Tennoji-Ku, Osaka, 543-8555, Japan. kenseiyahata@gmail.com.ORCID http://orcid.org/0000-0003-2100-090X
Kenichi KogaDepartment of Nephrology, Japanese Red Cross Osaka Hospital, 5-30 Fudegasaki-Cho, Tennoji-Ku, Osaka, 543-8555, Japan.
Daisuke HiraiDepartment of Nephrology, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa Mukaihata-Cho, Fushimi-Ku, Kyoto, 612-8555, Japan.
Koichi SetaDepartment of Nephrology, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa Mukaihata-Cho, Fushimi-Ku, Kyoto, 612-8555, Japan.
Keita P MoriCenter of Nephrology and Urology, Division of Nephrology and Dialysis, Medical Research Institute KITANO Hospital, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-Ku, Osaka, 530-8480, Japan.
Yoshiaki HigashiCenter of Nephrology and Urology, Division of Nephrology and Dialysis, Medical Research Institute KITANO Hospital, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-Ku, Osaka, 530-8480, Japan.
Tatsuo TsukamotoCenter of Nephrology and Urology, Division of Nephrology and Dialysis, Medical Research Institute KITANO Hospital, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-Ku, Osaka, 530-8480, Japan.
Akira IshiiDepartment of Nephrology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan.
Keiichi KanekoDepartment of Nephrology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan.
Motoko YanagitaDepartment of Nephrology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan.
Chiharu KinoshitaDepartment of Nephrology, Kyoto Min-Iren Chuo Hospital, 2-1 Uzumasa Tsuchimoto-Cho, Ukyo-Ku, Kyoto, 616-8147, Japan.
Keisuke OsakiDepartment of Nephrology, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, 650-0047, Japan.
Akihiro YoshimotoDepartment of Nephrology, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-Ku, Kobe, 650-0047, Japan.
Hiroaki HataDepartment of Surgery, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa Mukaihata-Cho, Fushimi-Ku, Kyoto, 612-8555, Japan.
Naoki SakaneDivision of Translational Research, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusa Mukaihata-Cho, Fushimi-Ku, Kyoto, 612-8555, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfection is a rare complication of percutaneous renal biopsy (RB). However, the questionnaire included in the Kidney Biopsy Guidebook 2020 in Japan revealed that antibiotic prophylaxis (AP) was administered at about 60% of hospitals. The objective of this study was to evaluate whether it is possible to omit AP for RB.

methodsPatients aged ≥ 15 years were eligible. Three hundred and sixty-four patients were recruited at 6 hospitals. The patients were randomly assigned to receive either a single dose of intravenous cefazolin or no antibiotic prophylaxis. The primary outcome was the percentage of patients that exhibited positive urine cultures 3 or 4 days after the RB. The secondary outcomes were the percentage of patients who were diagnosed with pyelonephritis, puncture site infections (PSI), or an infection other than pyelonephritis or PSI within 30 days, and cefazolin-induced side effects.

resultsWith regard to the primary outcome, there was no statistically significant difference between the cefazolin group and the no AP group (2.9% versus 5.1%, p = 0.416). With regard to the secondary outcomes, only one patient (who belonged to no AP group) developed pyelonephritis. This patient underwent urinary catheterization. No PSI occurred. There were no significant intergroup differences in any secondary outcomes.

conclusionThis study revealed the incidence of post-percutaneous RB infections was minimal. Although the outcomes of this study did not lead to the conclusion that it is unnecessary to use AP for RB, the obtained data suggest that the effects of such AP may not be clinically significant.

Indexed as

Anti-Bacterial AgentsAntibiotic ProphylaxisCefazolinKidneyAdultAgedBiopsyFemaleHumansJapanMaleMiddle AgedProspective StudiesPyelonephritisTreatment OutcomeAnti-Bacterial AgentsCefazolinAntibiotic prophylaxisPercutaneous renal biopsyRandomized controlled trial

Identifiers

PMID39565468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.